Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors
2024年5月22日 - 9:30PM
ビジネスワイヤ(英語)
Actio Biosciences, a biotechnology company leveraging a novel
platform approach to genetics and precision medicine to develop new
therapeutics that target shared underlying biology in both rare and
common diseases, today announced that Ben Cravatt, Ph.D., has
joined the company’s board of directors. Dr. Cravatt is professor
and Norton B. Gilula Chair of Chemical Biology in the Department of
Chemistry at The Scripps Research Institute. His research group is
interested in developing chemical proteomic technologies that
enable protein and drug discovery on a global scale and applying
these methods to characterize biochemical pathways that play
important roles in human physiology and disease.
“By combining genuine expertise across biology, chemistry and
genetics, Ben has pioneered an approach to drug discovery and
development that sits at the heart of Actio’s mission,” said David
Goldstein, Ph.D., co-founder and CEO of Actio. “We are thrilled to
welcome Ben to our board and look forward to working together to
discover and develop new life-changing medicines.”
“Years of research has taught us that the best targets are those
supported by human genetics – and it is becoming clear that
specific kinds of genetic information are especially informative,”
said Dr. Cravatt. “Actio’s laser-focused approach targeting genes
responsible for rare devastating diseases promises new treatments
for those diseases and a powerful framework for rational expansion
to more common indications sharing mechanistic biology.”
In addition to his role at Scripps, Dr. Cravatt is a co-founder
of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide
Therapeutics (acquired by Lundbeck Pharmaceuticals) and Vividion
Therapeutics (acquired by Bayer AG). His honors include a Wolf
Prize in Chemistry, a Searle Scholar Award, the Eli Lilly Award in
Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award,
the Royal Society of Chemistry Jeremy Knowles Award, and
memberships in the National Academy of Sciences, National Academy
of Medicine, and American Academy of Arts and Sciences. Dr. Cravatt
obtained his undergraduate education at Stanford University,
receiving a B.S. in biological sciences and a B.A. in history. He
received a Ph.D. from The Scripps Research Institute (TSRI) in 1996
and joined the faculty at TSRI in 1997.
About Actio Biosciences Actio Biosciences is leveraging
advances in precision medicine to develop new therapeutics that
target shared genetics in rare and common diseases—bringing
meaningful medicines from one to many. Applying its expertise in
genetics, drug discovery and data sciences, Actio seeks to identify
programs where both biological and technical risk can be minimized
to streamline the drug development process and bring forward
exceptionally potent and precisely targeted therapeutics. Founded
in October 2021, the San Diego-based company is led by leaders in
genetics and drug development and backed by top healthcare
investors. For more information, please visit
ActioBiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522603993/en/
Dan Budwick, 1AB dan@1abmedia.com